Mode
Text Size
Log in / Sign up
Phase 4 N=66 Randomized Quadruple-blind Treatment

IV Acetaminophen for Acute Post Operative Pain in C-Section Patients

Post-operative Pain

Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: Opioid Requirements in Cesarean Section (C-section) Patient Population — 44; 48; 58; 57 mg

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
IV Acetaminophen (Drug); Saline as placebo (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Montefiore Medical Center
Primary completion
Dec 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Opioid Requirements in Cesarean Section (C-section) Patient Population
44; 48; 58; 57
SECONDARY
Visual Analog Score (VAS) Pain Score
2.2; 1.4; 3.4; 3.6; 1.2; 2.3
SECONDARY
Percentage of Participants Reporting to be Wide Awake up to 72 Hours After the C-section
95; 95
SECONDARY
"Percentage of Patients With Adverse Events After the Surgery
22; 27; 21; 27; 57; 63
SECONDARY
Number of Participants Using Patient-controlled Analgesia (PCA) Attempts
SECONDARY
Percentage of Participants That Were Re-Hospitalized 1 Week After Discharge
0; 0
SECONDARY
Pain Medication Usage ( NSAIDS)
27; 30.3

Summary

Post-operative pain management after C-section is an important topic as the number of elective c-sections increases each year. Pain is managed either by giving opioids or by using non-opioids. The purpose of this study is to evaluate the effectiveness of IV Acetaminophen in pain relief and its impact in the usage of post-operative opioid requirements and opioid associated complications. The hypothesis is that four doses of IV Acetaminophen in conjunction with intrathecal or epidural morphine given to the patients after c-section will reduce post-operative opioid requirements and opioid associated complications.

Eligibility Criteria

Inclusion Criteria

  • Elective full term CS patients
  • Age 18 and above
  • ASA I-III

Exclusion Criteria

  • Allergic reaction to IV acetaminophen
  • Not able to understand and sign the research consent
  • Pregnancy induced hypertension or pre-eclampsia patients
  • Planned intensive care admission patients
  • Patients with severe hepatic impairment or active liver diseases (Two fold increase in any of the liver enzymes)
  • Patients with serum creatinine>2mg/dl
  • For nursing mothers, any evidence of hepatic dysfunction of the new born
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02069184). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search